Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Mesenchymal stem cells derived from canine umbilical cord vein--a novel source for cell therapy studies.

Zucconi E., Vieira NM., Bueno DF., Secco M., Jazedje T., Ambrosio CE.

Clinical Trial on Scar, published in Stem Cells Dev (2010) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cells Dev (2010)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
19290805
DOI
10.1089/scd.2008.0314

Abstract (original English)

The canine model provides a large animal system to evaluate many treatment modalities using stem cells (SCs). However, only bone marrow (BM) protocols have been widely used in dogs for preclinical approaches. BM donation consists of an invasive procedure and the number and differentiation potential of its mesenchymal stem cells (MSCs) decline with age. More recently, umbilical cord was introduced as an alternative source to BM since it is obtained from a sample that is routinely discarded. Here, we describe the isolation of MSCs from canine umbilical cord vein (cUCV). These cells can be obtained from every cord received and grow successfully in culture. Their multipotent plasticity was demonstrated by their capacity to differentiate in adipocytic, chondrocytic, and osteocytic lineages. Furthermore, our results open possibilities to use cUCV cells in preclinical trials for many well-characterized canine model conditions homologs to human diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAnimalsCell DifferentiationCell LineageCell ProliferationCell SeparationCells, CulturedChondrocytesDogsFlow Cytometry

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research